초점 초음파 절제술 시장 : 기술, 워크플로우, 시스템 유형, 환자 연령층, 용도, 최종사용자별 - 예측(2026-2032년)

The Focused Ultrasound Ablation Surgery Market was valued at USD 3.01 billion in 2025 and is projected to grow to USD 3.26 billion in 2026, with a CAGR of 9.84%, reaching USD 5.81 billion by 2032.

How the evolution of image-guided energy delivery and clinical protocols is reshaping adoption pathways for focused ultrasound ablation across specialty care settings

Focused ultrasound ablation has evolved from experimental interventions to an increasingly mainstream therapeutic modality across multiple clinical specialties. The technology couples precise energy delivery with image guidance to create noninvasive or minimally invasive tissue ablation, and its clinical promise lies in reducing perioperative morbidity, shortening recovery times, and enabling outpatient care pathways. In neurology, thermal ablation and neuromodulation approaches are being refined to target deep brain structures with millimetric precision for movement disorders and refractory epilepsy. In oncology, thermal and mechanical ablation techniques are being explored as organ-preserving alternatives or adjuncts to systemic therapy for focal tumors.

Concurrently, advances in imaging and transducer design have expanded procedural safety and expanded indications. The convergence of improved guidance platforms, enhanced thermal monitoring, and shorter procedural footprints is enabling broader adoption by hospitals, ambulatory surgical centers, and research institutes. Moreover, the maturation of standardized clinical protocols and the accumulation of medium-term outcome data have begun to shape payer conversations and hospital investment decisions. As clinicians and administrators weigh capital and operational choices, implementation strategies that align technology capability with institutional workflow and patient selection criteria are becoming paramount, guiding how programs scale and integrate focused ultrasound into standard care.

Key disruptive trends and technological improvements that are accelerating clinical adoption, altering care pathways, and shifting competitive imperatives in focused ultrasound ablation

The landscape for focused ultrasound ablation is undergoing transformative shifts driven by technological refinement, clinical evidence accumulation, and systemic pressures on healthcare delivery. Improved imaging fidelity and real-time thermometry have increased operator confidence, enabling expansion from single-indication pilots to multi-specialty programs. At the same time, modular system architectures and portable configurations are reducing procedural footprint and enabling greater procedural throughput, which in turn supports outpatient migration. In neurology, the refinement of targeting algorithms and the integration of neuro-navigation tools have broadened suitability for movement disorders beyond essential tremor, while oncology teams are experimenting with combination regimens that pair ablation with immunomodulatory approaches.

Parallel forces are influencing commercial dynamics. Providers are prioritizing capital that supports ambulatory and hybrid care models, creating demand for devices that demonstrate efficient workflow integration and predictable operating profiles. Research institutes and private centers are catalyzing adoption by generating comparative effectiveness evidence and hosting investigator-initiated studies. Finally, the shifting reimbursement landscape and greater emphasis on value-based outcomes are privileging technologies that demonstrably reduce length of stay, lower complication rates, and enable same-day discharge, thereby accelerating adoption in resource-constrained care environments.

How 2025 tariff adjustments are reshaping global supply chains, capital deployment decisions, and procurement risk assessments for focused ultrasound device stakeholders

United States tariff changes introduced in 2025 have created a more complex commercial environment for manufacturers, distributors, and healthcare providers engaged with focused ultrasound technologies. Tariff adjustments have increased landed costs for imported components and finished systems, particularly for high-precision transducer assemblies, RF electronics, and certain imaging subsystems that are commonly sourced from global suppliers. As a result, manufacturers have been prompted to reassess supply chain structures, prioritize local content strategies, and negotiate supplier agreements that mitigate cost volatility.

Clinicians and hospital procurement teams have felt downstream effects through extended lead times and periodic component shortages, which have in some instances delayed installation timelines for capital equipment. Moreover, the tariff environment has sharpened attention on total cost of ownership, including service contracts and consumable pricing, which influences procurement committees' vendor selection criteria. In response, several device makers have expanded regional repair centers, increased local inventory buffers, and accelerated partnerships with domestic suppliers to preserve pricing competitiveness and protect clinical uptime. These adaptive measures, together with proactive contracting strategies by providers, are serving to reduce disruption while reshaping how organizations evaluate vendor resilience and long-term partnership value.

A layered segmentation framework revealing how clinical indication, guidance technology, care setting, workflow, system architecture, and patient demographics define differentiated value propositions

Segmentation analysis reveals that focused ultrasound ablation technologies intersect a broad matrix of clinical applications, guidance modalities, care settings, workflows, hardware architectures, and patient populations, creating differentiated value propositions for each market segment. Within applications, neurology spans brain tumor management, epilepsy control, essential tremor relief, and Parkinson disease symptom modulation, while oncology encompasses focal treatments for kidney, liver, pancreatic, and prostate cancers. Urology applications address benign prostatic hyperplasia and kidney stones, and women's health focuses on adenomyosis and uterine fibroids. From a technology perspective, MRI-guided systems bifurcate into closed bore and open bore configurations that prioritize different imaging trade-offs, and ultrasound-guided systems differentiate between endoluminal and extracorporeal approaches based on access and focal depth requirements. End user segmentation includes ambulatory surgical centers that may be hospital-owned or standalone, hospitals that include private and public institutions, and research institutes composed of academic and private entities, each with distinct capital approval processes and clinical trial imperatives. Workflow distinctions between inpatient and outpatient care, with outpatient further subdivided into daycare surgery and office-based surgery, influence device selection, room design, and staffing models. System type considerations between multi-element and single-element architectures drive cost, focal control, and clinical versatility. Finally, patient age group segmentation differentiates adult and pediatric populations, with adult care further stratified by elderly and non-elderly cohorts to reflect differing comorbidity profiles and perioperative tolerance. Understanding these intersecting layers enables more precise clinical positioning, tailored training programs, and reimbursement strategies that reflect the nuanced needs of each clinical and operational context.

How regional healthcare infrastructure, reimbursement pathways, and manufacturing strategies are driving differentiated adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are shaping where and how focused ultrasound ablation systems are adopted, funded, and scaled. In the Americas, investment in outpatient infrastructure and a growing appetite for minimally invasive alternatives have incentivized hospital systems and ambulatory surgery centers to pilot integrated programs, while a dense private provider network supports rapid procedural diffusion across metropolitan markets. Europe, the Middle East & Africa present a heterogeneous landscape where regulatory harmonization, public hospital procurement cycles, and variable reimbursement policies influence adoption tempo; in several countries, centralized health technology assessment processes and national clinical networks have accelerated evidence generation and dissemination. Asia-Pacific exhibits strong growth drivers tied to rising procedural volumes, expanding private hospital capacity, and proactive local manufacturing initiatives, with some markets prioritizing technology transfer and domestic production to manage cost pressures.

Across regions, common themes emerge: the need for context-specific training pathways, the importance of aligning device capabilities with facility workflows, and the value of robust clinical evidence to support reimbursement negotiations. Consequently, successful regional strategies anticipate regulatory timelines, invest in local key opinion leader engagement, and design distribution models that reflect the operational realities of hospitals, ambulatory centers, and research institutes in each geography.

Strategic competitive behaviors, clinical partnership models, and service ecosystems that determine market leadership and long-term vendor-institution relationships

Competitive dynamics in focused ultrasound ablation are defined by a combination of clinical evidence leadership, system versatility, service and training ecosystems, and commercial partnerships. Leading manufacturers have focused on building robust clinical pipelines that demonstrate safety and efficacy across multiple indications, while also investing in modular hardware and software upgrades that enable incremental capability expansion without full-system replacement. Strategic alliances with imaging vendors and academic centers have accelerated real-world data collection and created pathways for investigator-initiated studies that inform guideline development.

Service models have become a competitive differentiator; organizations that combine device sales with comprehensive training programs, local maintenance networks, and outcome tracking platforms are more likely to secure long-term institutional partnerships. Additionally, aftermarket revenue streams from consumables, software licenses, and procedure-specific disposables are increasingly important to financial models. Partnerships between device manufacturers and hospital networks or ambulatory surgical groups have also emerged, facilitating pilot programs and bundled purchasing agreements. Finally, intellectual property portfolios and regulatory track records matter: companies with cleared device claims across multiple indications and geographies can leverage those credentials to accelerate adoption and negotiate favorable procurement terms with large health systems.

Actionable strategic imperatives for manufacturers, clinical program leaders, and payers to accelerate adoption, secure procurement, and de-risk supply chain exposure

Industry leaders should pursue a set of coordinated actions to convert clinical promise into sustainable commercial performance. First, align product roadmaps with prioritized clinical use cases by concentrating development resources on indications that offer clear reductions in hospital resource utilization and improved patient-centric outcomes. Second, invest in scalable training curricula and proctoring programs that lower the adoption barrier for community hospitals and ambulatory surgical centers, while simultaneously capturing procedural data for outcomes validation. Third, strengthen supply chain resilience by diversifying sourcing, qualifying regional suppliers, and increasing spare parts inventories to minimize clinical disruptions from trade policy shifts. Fourth, develop flexible commercial models that include capital leases, outcome-based contracting, and bundled service packages to address procurement preferences across public and private hospitals.

Moreover, foster payer engagement early by generating cost-effectiveness evidence and real-world outcome datasets that demonstrate reduced length of stay and complication rates. Engage in targeted regional strategies by partnering with local manufacturing or service providers where tariffs or logistic challenges pressure total cost of ownership. Finally, prioritize interoperability and software-driven service offerings that enable remote monitoring, predictive maintenance, and outcomes tracking, thereby creating recurring revenue streams and deepening client relationships.

A rigorous mixed-method research approach combining stakeholder interviews, clinical evidence synthesis, supply chain mapping, and cross-validation to support actionable strategic guidance

The research methodology underpinning this analysis combined primary stakeholder engagement with structured secondary evidence synthesis and triangulation to ensure robustness and relevance. Primary research included in-depth interviews with clinical leaders across neurology, oncology, urology, and women's health, discussions with procurement and operations executives from ambulatory surgical centers and hospitals, and consultations with regulatory and reimbursement specialists to understand regional decision frameworks. Secondary research encompassed peer-reviewed clinical literature, clinical trial registries, device labeling and clearance documents, patent filings, and industry press that highlights strategic partnerships and product launches. Supply chain assessments integrated supplier mapping, import tariff schedules, and distributor models to identify potential bottlenecks and mitigation pathways.

Data were synthesized using a cross-validation approach that reconciled clinician perspectives, commercial intelligence, and regulatory context. Where evidence gaps existed, scenario-based analysis was used to articulate plausible operational impacts and strategic responses. The methodology prioritized transparency, noting the provenance of primary insights and the limitations of indirect evidence, and emphasized actionable conclusions designed to inform procurement decisions, clinical program design, and strategic investment prioritization.

Synthesis of clinical, commercial, and operational determinants that will govern whether focused ultrasound ablation fulfills its potential to transform procedural care delivery

Focused ultrasound ablation stands at an inflection point where clinical maturity and commercial viability intersect, offering health systems a pathway to reduce procedural invasiveness and enhance patient throughput. The technology's expansion across neurology, oncology, urology, and women's health is supported by iterative improvements in imaging guidance, transducer technology, and procedural workflows that favor outpatient care. Nevertheless, adoption will be mediated by pragmatic considerations including device interoperability, clinician training, reimbursement alignment, and supply chain resilience in the face of trade policy shifts.

Strategic success will accrue to organizations that align product development with high-value clinical use cases, invest in scalable training and service ecosystems, and engage payers with robust real-world evidence. Regional strategies that account for regulatory heterogeneity and manufacturing localization will further reduce procurement friction. In short, focused ultrasound ablation can meaningfully alter clinical pathways and institutional economics, but realizing that potential requires coordinated action across clinical, commercial, and operational dimensions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Focused Ultrasound Ablation Surgery Market, by Technology

• 8.1. Mri Guided
  • 8.1.1. Closed Bore
  • 8.1.2. Open Bore
• 8.2. Ultrasound Guided
  • 8.2.1. Endoluminal
  • 8.2.2. Extracorporeal

9. Focused Ultrasound Ablation Surgery Market, by Workflow

• 9.1. Inpatient
• 9.2. Outpatient
  • 9.2.1. Daycare Surgery
  • 9.2.2. Office Based Surgery

10. Focused Ultrasound Ablation Surgery Market, by System Type

• 10.1. Multi Element
• 10.2. Single Element

11. Focused Ultrasound Ablation Surgery Market, by Patient Age Group

• 11.1. Adult
  • 11.1.1. Elderly
  • 11.1.2. Non Elderly
• 11.2. Pediatric

12. Focused Ultrasound Ablation Surgery Market, by Application

• 12.1. Neurology
  • 12.1.1. Brain Tumor
  • 12.1.2. Epilepsy
  • 12.1.3. Essential Tremor
  • 12.1.4. Parkinson Disease
• 12.2. Oncology
  • 12.2.1. Kidney Cancer
  • 12.2.2. Liver Cancer
  • 12.2.3. Pancreatic Cancer
  • 12.2.4. Prostate Cancer
• 12.3. Urology
  • 12.3.1. Benign Prostatic Hyperplasia
  • 12.3.2. Kidney Stones
• 12.4. Women Health
  • 12.4.1. Adenomyosis
  • 12.4.2. Uterine Fibroids

13. Focused Ultrasound Ablation Surgery Market, by End User

• 13.1. Ambulatory Surgical Centers
  • 13.1.1. Hospital Owned Centers
  • 13.1.2. Standalone Centers
• 13.2. Hospitals
  • 13.2.1. Private Hospitals
  • 13.2.2. Public Hospitals
• 13.3. Research Institutes
  • 13.3.1. Academic Institutes
  • 13.3.2. Private Institutes

14. Focused Ultrasound Ablation Surgery Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Focused Ultrasound Ablation Surgery Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Focused Ultrasound Ablation Surgery Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Focused Ultrasound Ablation Surgery Market

18. China Focused Ultrasound Ablation Surgery Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Alpinion Medical Systems Co Ltd
• 19.6. Blatek Industries Inc
• 19.7. Boston Scientific Corporation
• 19.8. Changjiangyuan Technology Development Co Ltd
• 19.9. Chongqing Haifu Medical Equipment Co., Ltd.
• 19.10. EDAP TMS S.A.
• 19.11. FUS Foundation
• 19.12. GE HealthCare Technologies Inc
• 19.13. HistoSonics, Inc.
• 19.14. Hitachi, Ltd.
• 19.15. Hologic Inc
• 19.16. Image Guided Therapy S.A.
• 19.17. Insightec Ltd.
• 19.18. Koninklijke Philips N.V.
• 19.19. Medtronic plc
• 19.20. Profound Medical Corp.
• 19.21. Samsung Medison Co Ltd
• 19.22. Shanghai A&S Technology Development Co Ltd
• 19.23. Siemens Healthineers AG
• 19.24. Sonablate Corp
• 19.25. SonaCare Medical LLC
• 19.26. Supersonic Imagine SA
• 19.27. Theraclion S.A.
• 19.28. Thermogrid Technologies Inc
• 19.29. Wikkon Medical Technology Co Ltd
• 19.30. ZONARE Medical Systems Inc